

## PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



### ADAR2 (R510) Peptide

Cat No.: BS2026P

#### Background

ADAR2, also designated adenosine deaminase, RNA-specific (RED1), RNA-editing enzyme 1, DRABA2, DRADA2, ADAR2 $\alpha$ -L1, ADAR2 $\alpha$ -L2 and ADAR2 $\alpha$ -L3, mediates RNA editing by destabilizing RNA through deamination of adenosine to inosine. ADAR2 is responsible for pre-mRNA editing of the glutamate receptor subunit B by site-specific deamination of adenosines. It can modify its own pre-mRNA and generate new splice sites. Translocation of endogenous ADAR2 from the nucleolus to the nucleoplasm results in increased editing of endogenous ADAR2 substrates. Alternative splicing of this gene results in several transcript variants that may influence RNA editing. RNA editing involves the deamination of adenosines at specific sites, the result of which can be a change in the amino acid sequence of the protein so that it differs from that predicted by the sequence of the DNA.

#### Swiss-Prot

P78563

#### Applications

#### Blocking

#### Specificity

This peptide can be used with studies using BS2026 ADAR2 (R510) pAb.

#### Purification & Purity

Synthetic peptide ADAR2 (R510). (Note: the amino acid sequence is proprietary). The purity is > 98%.

#### Product

1 mg/ml in DI water.

#### Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

#### Research Use

For research use only, not for use in diagnostic procedure.